dr. mcgregor on choosing a combination therapy regimen in advanced rcc
Published 4 years ago • 100 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
1:16
dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
-
2:06
dr. mcgregor on whether patients need frontline combinations in rcc
-
1:14
dr. mcgregor on the combination of atezolizumab and bevacizumab in rcc
-
1:49
dr. mcgregor on immunotherapy combinations in kidney cancer
-
1:03
dr. mcgregor on the evolving treatment landscape of rcc
-
1:22
copy of dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
0:53
dr. mcgregor on challenges facing frontline treatments for rcc
-
7:53
selecting an optimal second-line regimen for mrcc
-
2:18
dr. joseph on selecting frontline therapy in mrcc
-
9:05
mrcc: when is tki/i-o combination therapy appropriate?
-
0:59
dr. mcgregor on future research in mcrpc
-
10:15
novel combinations in mrcc: axi/pembro vs axi/avelumab
-
0:54
dr. rini on sequencing of immunotherapy combinations in rcc
-
1:54
dr. mcgregor on immunotherapy in rare genitourinary cancers
-
1:19
the connection between your gut and your brain
-
1:59
dr. shuch on considerations for appropriate treatment in advanced rcc
-
2:35
historical perspectives on the treatment of mrcc
-
26:45
rationale for selecting combinations with immunotherapy | howard gurney, mbbs, fracp
-
5:54
adjuvant sunitinib’s role in the treatment of rcc